Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 130

1.

Activation of the inflammation, coagulation, and fibrinolysis systems, without influence of abciximab infusion in patients with non-ST-elevation acute coronary syndromes treated with dalteparin: a GUSTO IV substudy.

James SK, Siegbahn A, Armstrong P, Barnathan E, Califf R, Simoons ML, Wallentin L.

Am Heart J. 2004 Feb;147(2):267-74.

PMID:
14760324
[PubMed - indexed for MEDLINE]
2.

Effect of Abciximab on prothrombin activation and thrombin generation in acute coronary syndromes without ST-segment elevation: Global Utilization of Strategies to Open Occluded Coronary Arteries Trial IV in Acute Coronary Syndromes (GUSTO IV ACS) Italian Hematologic Substudy.

Merlini PA, Repetto A, Lombardi A, Vetrano A, Fetiveau R, Cavallini C, Sappè D, Salvioni A, Canziani R, Savonitto S, Mannucci PM, Ardissino D.

Circulation. 2002 Feb 26;105(8):928-32.

PMID:
11864920
[PubMed - indexed for MEDLINE]
Free Article
3.

Long-term results after the glycoprotein IIb/IIIa inhibitor abciximab in unstable angina: one-year survival in the GUSTO IV-ACS (Global Use of Strategies To Open Occluded Coronary Arteries IV--Acute Coronary Syndrome) Trial.

Ottervanger JP, Armstrong P, Barnathan ES, Boersma E, Cooper JS, Ohman EM, James S, Topol E, Wallentin L, Simoons ML; GUSTO IV-ACS Investigators.

Circulation. 2003 Jan 28;107(3):437-42.

PMID:
12551868
[PubMed - indexed for MEDLINE]
Free Article
5.

Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes.

James S, Armstrong P, Califf R, Husted S, Kontny F, Niemminen M, Pfisterer M, Simoons ML, Wallentin L.

Eur Heart J. 2002 Oct;23(19):1538-45.

PMID:
12242074
[PubMed - indexed for MEDLINE]
6.

Randomized COMparison of platelet inhibition with abciximab, tiRofiban and eptifibatide during percutaneous coronary intervention in acute coronary syndromes: the COMPARE trial. Comparison Of Measurements of Platelet aggregation with Aggrastat, Reopro, and Eptifibatide.

Batchelor WB, Tolleson TR, Huang Y, Larsen RL, Mantell RM, Dillard P, Davidian M, Zhang D, Cantor WJ, Sketch MH Jr, Ohman EM, Zidar JP, Gretler D, DiBattiste PM, Tcheng JE, Califf RM, Harrington RA.

Circulation. 2002 Sep 17;106(12):1470-6.

PMID:
12234950
[PubMed - indexed for MEDLINE]
Free Article
7.

Leukocyte-platelet aggregation, platelet surface P-selectin, and platelet surface glycoprotein IIIa after percutaneous coronary intervention: Effects of dalteparin or unfractionated heparin in combination with abciximab.

Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Pieper K, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL 3rd, Michelson AD.

Am Heart J. 2001 Nov;142(5):790-8.

PMID:
11685164
[PubMed - indexed for MEDLINE]
8.
9.

An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease.

James SK, Oldgren J, Lindbäck J, Johnston N, Siegbahn A, Wallentin L.

Am Heart J. 2005 Apr;149(4):619-26.

PMID:
15990743
[PubMed - indexed for MEDLINE]
10.

Quantification of abciximab-induced platelet inhibition is assay dependent: a comparative study in patients undergoing percutaneous coronary intervention.

Furman MI, Kereiakes DJ, Krueger LA, Mueller MN, Broderick TM, Schneider JF, Howard WL, Fox ML, Barnard MR, Frelinger AL 3rd, Michelson AD.

Am Heart J. 2003 Feb;145(2):e6.

PMID:
12595861
[PubMed - indexed for MEDLINE]
11.

Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.

Oldgren J, Fellenius C, Boman K, Jansson JH, Nilsson TK, Wallentin L, Siegbahn A.

J Intern Med. 2005 Nov;258(5):420-7.

PMID:
16238677
[PubMed - indexed for MEDLINE]
12.

Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST-elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention.

Boersma E, Akkerhuis KM, Théroux P, Califf RM, Topol EJ, Simoons ML.

Circulation. 1999 Nov 16;100(20):2045-8. Review.

PMID:
10562258
[PubMed - indexed for MEDLINE]
Free Article
13.

Effects of platelet glycoprotein IIb/IIIa inhibition with abciximab on thrombin generation and activity during percutaneous coronary intervention.

Dangas G, Marmur JD, King TE, De Leon J, Sharma SK, Vidhun R, Feldman D, Stoynov MY, Badimon JJ, Ambrose JA.

Am Heart J. 1999 Jul;138(1 Pt 1):49-54.

PMID:
10385763
[PubMed - indexed for MEDLINE]
14.

Thrombin generation and fibrinolytic activities among patients receiving reduced-dose alteplase plus abciximab or undergoing direct angioplasty plus abciximab for acute myocardial infarction.

Mak KH, Lee LH, Wong A, Chan C, Koh TH, Lau KW, Lim YL.

Am J Cardiol. 2002 Apr 15;89(8):930-6.

PMID:
11950430
[PubMed - indexed for MEDLINE]
15.

[Non ST elevation acute coronary syndrome. Some characteristics of coagulation and von Willebrand factor during short term use of ticlopidine or clopidogrel].

Averkov OV, Slavina NN, Gratsianskiĭ NA.

Kardiologiia. 2003;43(10):50-9. Russian.

PMID:
14593356
[PubMed - indexed for MEDLINE]
16.

Comparative pharmacodynamic evaluation of eptifibatide and abciximab in patients with non-ST-segment elevation acute coronary syndromes: the TAM2 study.

Saucedo JF, Lui HK, Garza L, Guerra GJ, Jacoski MV, Jennings LK.

J Thromb Thrombolysis. 2004 Oct;18(2):67-74. Erratum in: J Thromb Thrombolysis. 2005 Apr;19(2):139. Dosage error in published abstract; MEDLINE/PubMed abstract corrected.

PMID:
15789173
[PubMed - indexed for MEDLINE]
17.

Abciximab suppresses the rise in levels of circulating inflammatory markers after percutaneous coronary revascularization.

Lincoff AM, Kereiakes DJ, Mascelli MA, Deckelbaum LI, Barnathan ES, Patel KK, Frederick B, Nakada MT, Topol EJ.

Circulation. 2001 Jul 10;104(2):163-7.

PMID:
11447080
[PubMed - indexed for MEDLINE]
Free Article
18.

Spotlight on abciximab in patients with ischemic heart disease undergoing percutaneous coronary revascularization.

Ibbotson T, McGavin JK, Goa KL.

Am J Cardiovasc Drugs. 2003;3(5):381-6. Review.

PMID:
14728074
[PubMed - indexed for MEDLINE]
19.

Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.

Dangas G, Badimon JJ, Coller BS, Fallon JT, Sharma SK, Hayes RM, Meraj P, Ambrose JA, Marmur JD.

Arterioscler Thromb Vasc Biol. 1998 Aug;18(8):1342-9.

PMID:
9714143
[PubMed - indexed for MEDLINE]
Free Article
20.

TARGET versus GUSTO-IV: appropriate use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes and percutaneous coronary intervention.

Kandzari DE, Califf RM.

Curr Opin Cardiol. 2002 Jul;17(4):332-9. Review.

PMID:
12151865
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk